Foundation-directed therapeutic development in Huntington's disease.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2014-02-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm4009295PMID 24432836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Huntington disease

  2015cited by this paper
• Discovery of a novel aggregation domain in the huntingtin protein: implications for the mechanisms of Htt aggregation and toxicity.

  2013cited by this paper
• Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

  2013cited by this paper
• Metabolic network as a progression biomarker of premanifest Huntington's disease.

  2013cited by this paper
• Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

  2013cited by this paper
• Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease

  2013cited by this paper
• HDAC4 Reduction: A Novel Therapeutic Strategy to Target Cytoplasmic Huntingtin and Ameliorate Neurodegeneration

  2013cited by this paper
• Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study.

  2013cited by this paper
• Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II

  2012cited by this paper
• Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

  2012cited by this paper
• TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease.

  2012cited by this paper
• Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum

  2012cited by this paper
• Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

  2012cited by this paper
• Fibrillar Structure and Charge Determine the Interaction of Polyglutamine Protein Aggregates with the Cell Surface*

  2012cited by this paper
• Kynurenines in the CNS: recent advances and new questions

  2012cited by this paper
• Promoters Are Differentially Sensitive to N-Terminal Mutant Huntingtin-Mediated Transcriptional Repression

  2012cited by this paper
• Kynurenines in the mammalian brain: when physiology meets pathology

  2012cited by this paper
• Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.

  2012cited by this paper
• Mouse Models of Polyglutamine Diseases: Review and Data Table. Part I

  2012cited by this paper
• Brain Structure in Preclinical Huntington's Disease: A Multi-Method Approach

  2012cited by this paper
• Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's Disease

  2012cited by this paper
• Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-In Mouse Model of Huntington's Disease

  2012cited by this paper
• The role of IκB kinase complex in the neurobiology of Huntington's disease.

  2011cited by this paper
• Huntington's Disease: Can Mice Lead the Way to Treatment?

  2011cited by this paper
• Kinase inhibitors modulate huntingtin cell localization and toxicity.

  2011cited by this paper
• Huntington's Disease: Can Mice Lead the Way to Treatment?

  2011cited by this paper
• Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease.

  2011cited by this paper
• Brain networks in Huntington disease.

  2011cited by this paper
• Oligonucleotide therapeutic approaches for Huntington disease.

  2011cited by this paper
• Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.

  2011cited by this paper
• Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease

  2011cited by this paper
• Protein Interactions and Target Discovery in Huntington’s Disease

  2011cited by this paper
• The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

  2011cited by this paper
• SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease

  2011cited by this paper
• Small Changes, Big Impact

  2011cited by this paper
• Dopamine and Glutamate in Huntington's Disease: A Balancing Act

  2010cited by this paper
• "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness.

  2010cited by this paper
• Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo

  2010cited by this paper
• Hypothalamic and neuroendocrine changes in Huntington's disease.

  2010cited by this paper
• QEEG Measures in Huntington's Disease: A Pilot Study

  2010cited by this paper
• Molecular mechanisms and potential therapeutical targets in Huntington's disease.

  2010cited by this paper
• Acetylation targets mutant huntingtin to autophagosomes for degradation.

  2009cited by this paper
• Huntington's disease: the case for genetic modifiers

  2009cited by this paper
• Small molecule drug discovery for Huntington's Disease.

  2009cited by this paper
• Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT‐HD study

  2009cited by this paper
• Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease

  2009cited by this paper
• Polyglutamine disruption of the huntingtin exon1 N-terminus triggers a complex aggregation mechanism

  2009cited by this paper
• Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

  2009cited by this paper
• Huntingtin as an essential integrator of intracellular vesicular trafficking.

  2009cited by this paper
• The Chaperonin TRIC Blocks a Huntingtin Sequence Element that promotes the Conformational Switch to Aggregation

  2009cited by this paper
• Polyglutamine expansion in huntingtin alters its interaction with phospholipids

  2009cited by this paper
• Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons.

  2008cited by this paper
• Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study.

  2007cited by this paper
• Wild-type huntingtin plays a role in brain development and neuronal survival

  2007cited by this paper
• Brain structure in preclinical Huntington's disease.

  2006cited by this paper
• Normal huntingtin function: an alternative approach to Huntington's disease

  2005cited by this paper
• Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.

  2004cited by this paper
• Huntingtin Bodies Sequester Vesicle-Associated Proteins by a Polyproline-Dependent Interaction

  2004cited by this paper
• On chorea. George Huntington, M.D.

  2003cited by this paper
• Mutant Huntingtin Causes Context-Dependent Neurodegeneration in Mice with Huntington's Disease

  2003cited by this paper
• Polyglutamine expansion neurodegenerative disease.

  2001cited by this paper
• Expansion explosion: new clues to the pathogenesis of repeat expansion neurodegenerative diseases.

  2001cited by this paper
• Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles.

  2000cited by this paper
• Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.

  1998cited by this paper
• Huntington disease.

  1998cited by this paper
• HEAT repeats in the Huntington's disease protein

  1995cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates.

  1990cited by this paper
• Huntington disease in Maryland: clinical aspects of racial variation.

  1987cited by this paper
• BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS

  1981cited by this paper
• Huntington's disease in black kindreds in South Carolina.

  1981cited by this paper
• The prevalence of Huntington's chorea in South Africa.

  1980cited by this paper
• Chorea

  1954cited by this paper
• Bmc Developmental Biology Inactivation of the Huntington's Disease Gene (hdh) Impairs Anterior Streak Formation and Early Patterning of the Mouse Embryo

  year unknowncited by this paper

• Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities

  2024cites this paper
• Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.

  2023cites this paper
• Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validation

  2022cites this paper
• Synthesis and Evaluation of a Fluorine-18 Radioligand for Imaging Huntingtin Aggregates by Positron Emission Tomographic Imaging

  2021cites this paper
• Surfactant modulation effect on the fluorescence emission of a dual-fluorophore: Realizing a single discriminative sensor for identifying different proteins in aqueous solutions

  2019cites this paper
• Major Developments in the Design of Inhibitors along the Kynurenine Pathway

  2017cites this paper
• Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases.

  2015cites this paper
• The clinical utility of multidisciplinary rehabilitation in individuals with Huntington’s Disease

  2015cites this paper
• Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists.

  2015cites this paper
• Targets for future clinical trials in Huntington's disease: What's in the pipeline?

  2014cites this paper